Research Progress of Oral Anticoagulation Management in Atrial Fibrillation Patients With End-stage Renal Disease
10.3969/j.issn.1000-3614.2025.06.010
- VernacularTitle:心房颤动合并终末期肾病患者的口服抗凝治疗进展
- Author:
He LUO
1
;
Yifeng ZHOU
1
;
Jingang ZHENG
1
Author Information
1. 中日友好医院 心脏科,北京 100029
- Publication Type:Journal Article
- Keywords:
atrial fibrillation;
end-stage renal disease;
renal failure;
warfarin;
direct oral anticoagulants
- From:
Chinese Circulation Journal
2025;40(6):619-623
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality rate of cardiogenic stroke caused by atrial fibrillation is high,and anticoagulant therapy is the first therapeutic choice in the management of atrial fibrillation.International normalized ratio of warfarin should be strictly controlled at 2.0-3.0.The efficacy of direct oral anticoagulants for preventing embolism events is non-inferior to warfarin,but the risk of bleeding is significantly lower.Severe renal function decline has a great impact on the efficacy and safety of oral anticoagulants.The use of oral anticoagulants in patients with end-stage renal disease is now still controversial.This article reviews the research progress of oral anticoagulant therapy in patients with non-valvular atrial fibrillation complicated with end-stage renal disease.
